Literature DB >> 22230600

Outcomes after open surgery and endovascular aneurysm repair for abdominal aortic aneurysm in patients with massive neck atheroma.

K Hoshina1, A Hosaka, T Takayama, M Kato, N Ohkubo, H Okamoto, K Shigematsu, T Miyata.   

Abstract

OBJECTIVE: We retrospectively analysed surgically treated abdominal aortic aneurysm (AAA) in patients with massive atheroma in the aneurysmal neck and compared the outcomes of endovascular aneurysm repair (EVAR) and open surgery (OS) to determine an appropriate strategy for massive neck atheroma cases.
METHODS: A retrospective study was performed in 326 consecutive patients who underwent EVAR and in 247 patients who underwent OS. We defined massive neck atheromas if the following characteristics were observed: (1) thickness ≥ 5 mm; (2) the circumference of the infrarenal aorta ≥ 75%; and (3) length ≥ 5 mm. Twenty-eight patients (8.5%) in the EVAR group and 22 (8.9%) in the OS group met these criteria. We modified the previously published reporting standards on the basis of the selection of systemic and embolisation-related complications.
RESULTS: Patients in the EVAR group had less intra-operative blood loss, shorter operation time, and shorter hospital stays after the operation (P < 0.01). No perioperative deaths were observed in either group. Major complications were categorised as early (in-hospital) or late (outpatient, within 6 months). Five and three patients in the OS and EVAR groups had early complications, but the difference was not statistically significant. In contrast, 7 patients in the EVAR group had late complications, compared to no patients in the OS group (P = 0.01). Kaplan-Meier analysis revealed a significantly higher survival rate in the OS group (P = 0.011). Two of the 4 patients with suprarenal clamping developed major complications. Mild eosinophilia was observed in 10 patients in the EVAR group. Proteinuria occurred or worsened in 5 EVAR patients and 1 OS patient.
CONCLUSION: Compared to OS patients, EVAR patients with massive neck atheroma tend to develop late-phase complications possibly related to cholesterol crystal embolisation. The clinical features of massive neck atheroma patients receiving EVAR should be carefully monitored even after hospital discharge.
Copyright © 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22230600     DOI: 10.1016/j.ejvs.2011.11.023

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  11 in total

1.  Statins reduce extensive aortic atheromas in patients with abdominal aortic aneurysms.

Authors:  Masaru Nemoto; Katsuyuki Hoshina; Toshio Takayama; Sumio Miura; Tatsu Nakazawa; Masaaki Kato; Kunihiro Shigematsu; Tetsuro Miyata; Toshiaki Watanabe
Journal:  Ann Vasc Dis       Date:  2013-11-15

2.  Is Endovascular Aneurysm Repair a Relative Contraindication for Patients with Preoperative Renal Dysfunction?

Authors:  Tadashi Furuyama; Toshihiro Onohara; Keita Mikasa; Jyunji Kishimoto; Masafumi Yamashita; Minoru Okamoto; Tsuyoshi Yamamoto; Yasushi Shimoe; Masahiro Okada; Toshiki Takahashi; Yoshimitsu Ishibashi; Mikizou Nakai; Hitoshi Suhara; Fuminari Kasashima; Masamitsu Endo; Takeshi Nishina; Jyunichi Kei; Akihiro Mizuno; Nobuhiro Handa
Journal:  Ann Vasc Dis       Date:  2015-08-18

3.  Feasibility of endovascular abdominal aortic aneurysm repair outside of the instructions for use and morphological changes at 3 years after the procedure.

Authors:  Katsuyuki Hoshina; Takuya Hashimoto; Masaaki Kato; Nobukazu Ohkubo; Kunihiro Shigematsu; Tetsuro Miyata
Journal:  Ann Vasc Dis       Date:  2014-02-28

4.  A perioperative strategy for abdominal aortic aneurysm in patients with chronic renal insufficiency.

Authors:  Makoto Haga; Katsuyuki Hoshina; Kunihiro Shigematsu; Toshiaki Watanabe
Journal:  Surg Today       Date:  2015-12-08       Impact factor: 2.549

5.  Study Design of PROCEDURE Study. A Randomized Comparison of the Dose-Dependent Effects of Pitavastatin in Patients with Abdominal Aortic Aneurysm with Massive Aortic Atheroma: Prevention of Cholesterol Embolization during Endovascular and Open Aneurysm Repair with Pitavastatin (PROCEDURE) Study.

Authors:  Katsuyuki Hoshina; Masaru Nemoto; Takuya Hashimoto; Sumio Miura; Go Urabe; Tatsu Nakazawa; Akihiro Hosaka; Masaaki Kato; Nobukazu Ohkubo; Takeshi Miyairi; Hiroyuki Okamoto; Kunihiro Shigematsu; Tetsuro Miyata
Journal:  Ann Vasc Dis       Date:  2013-02-15

6.  Aneurysmal degeneration and type Ib endoleak with proximal aneurysm rupture: A case report, review of literature and technical suggestions.

Authors:  Ali Kordzadeh; Harriet Scott; Nicholas Railton; Yiannis P Panayiotopoulos
Journal:  Ann Med Surg (Lond)       Date:  2014-03-05

7.  Theoretical mechanism of temporary renal function improvement after abdominal aortic aneurysm surgery: Applications for clinical imaging and laboratory data.

Authors:  Katsuyuki Hoshina; Takafumi Akai; Marie Ohshima; Toshiaki Watanabe; Sota Yamamoto
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 8.  Open versus Endovascular Repair of Abdominal Aortic Aneurysm in the Elective and Emergent Setting in a Pooled Population of 37,781 Patients: A Systematic Review and Meta-Analysis.

Authors:  Dustin M Thomas; Edward A Hulten; Shane T Ellis; David M F Anderson; Nathan Anderson; Fiora McRae; Jamil A Malik; Todd C Villines; Ahmad M Slim
Journal:  ISRN Cardiol       Date:  2014-04-02

9.  A case of anastomotic stenosis of the small intestine caused by cholesterol crystal embolism.

Authors:  Koji Murono; Kazushige Kawai; Keisuke Hata; Shigenobu Emoto; Manabu Kaneko; Kazuhito Sasaki; Takeshi Nishikawa; Kensuke Otani; Toshiaki Tanaka; Masako Ikemura; Hiroaki Nozawa
Journal:  Surg Case Rep       Date:  2018-04-04

10.  Outcomes of Endovascular Repair for Abdominal Aortic Aneurysms: A Nationwide Survey in Japan.

Authors:  Katsuyuki Hoshina; Shin Ishimaru; Yusuke Sasabuchi; Hideo Yasunaga; Kimihiro Komori
Journal:  Ann Surg       Date:  2019-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.